CD79B and primary central nervous system lymphoma: Although further investigation of the molecular mechanisms of BTK inhibitors is needed, the addition of BTK inhibitor to the R‐MPV might improve prognosis in patients with PCNSL harboring wild‐type CD79B because these patients were expected to be less responsive to the R‐MPV in our cohort.